



DOCKET NO.: MGH 1320.0 (MGH-0026)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jack Wands and Jens Encke

Confirmation No.: 3498

Application No.: 09/600,493

Group Art Unit: 1632

Filing Date: July 18, 2000

Examiner: Louis D. Lieto

**For: GENETIC IMMUNIZATION WITH NONSTRUCTURAL PROTEINS OF
HEPATITIS C VIRUS**

EXPRESS MAIL LABEL NO: EV670670692US

DATE OF DEPOSIT: October 27, 2005

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

11/01/2005 BABRAHA1 00000119 233050 09600493

01 FC:1806 180.00 DA

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☒ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☒ A copy of reference number 1 listed on the attached Form PTO-1449 is enclosed herewith.

☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: October 27, 2005

A handwritten signature in black ink, appearing to read "Phillip A. Singer", is written over a horizontal line.

Phillip A. Singer
Registration No. 40,176

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Sheet 1 of 1

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. MGH 1320.0 (MGH-0026)	Application No. 09/600,493
		Applicant Jack Wands and Jens Encke	
		Filing Date July 18, 2000	Group 1632
		Confirmation No. 3498	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Yoo, et al., "5' End-Dependent Translation Initiation of Hepatitis C Viral RNA and the Presence of Putative Positive and Negative Translational Control Elements with the 5' Untranslated Region", <i>Virology</i> 191 , 889-899, 1992	
EXAMINER		DATE CONSIDERED	



DOCKET NO.: MGH 1320.0 (MGH-0026)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jack Wands, Jen Encke

Confirmation No.: 3498

Application No.: 09/600,493

Group Art Unit: 1632

Filing Date: July 18, 2000

Examiner: Louis D. Lieto

For: GENETIC IMMUNIZATION WITH NONSTRUCTURAL PROTEINS OF
HEPATITIS C VIRUS

EXPRESS MAIL LABEL NO: EV670670692US
DATE OF DEPOSIT: October 27, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

In accordance with 37 CFR § 1.97(e), certification is hereby made that:

- ☐ Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
- ☒ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Date: October 27, 2005


Phillip A. Singer
Registration No. 40,176

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439